Tetracycline-Inactivating Enzymes

Tetracyclines have been foundational antibacterial agents for more than 70 years. Renewed interest in tetracycline antibiotics is being driven by advancements in tetracycline synthesis and strategic scaffold modifications designed to overcome established clinical resistance mechanisms including effl...

Descripción completa

Detalles Bibliográficos
Autores principales: Markley, Jana L., Wencewicz, Timothy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988894/
https://www.ncbi.nlm.nih.gov/pubmed/29899733
http://dx.doi.org/10.3389/fmicb.2018.01058
_version_ 1783329371407253504
author Markley, Jana L.
Wencewicz, Timothy A.
author_facet Markley, Jana L.
Wencewicz, Timothy A.
author_sort Markley, Jana L.
collection PubMed
description Tetracyclines have been foundational antibacterial agents for more than 70 years. Renewed interest in tetracycline antibiotics is being driven by advancements in tetracycline synthesis and strategic scaffold modifications designed to overcome established clinical resistance mechanisms including efflux and ribosome protection. Emerging new resistance mechanisms, including enzymatic antibiotic inactivation, threaten recent progress on bringing these next-generation tetracyclines to the clinic. Here we review the current state of knowledge on the structure, mechanism, and inhibition of tetracycline-inactivating enzymes.
format Online
Article
Text
id pubmed-5988894
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59888942018-06-13 Tetracycline-Inactivating Enzymes Markley, Jana L. Wencewicz, Timothy A. Front Microbiol Microbiology Tetracyclines have been foundational antibacterial agents for more than 70 years. Renewed interest in tetracycline antibiotics is being driven by advancements in tetracycline synthesis and strategic scaffold modifications designed to overcome established clinical resistance mechanisms including efflux and ribosome protection. Emerging new resistance mechanisms, including enzymatic antibiotic inactivation, threaten recent progress on bringing these next-generation tetracyclines to the clinic. Here we review the current state of knowledge on the structure, mechanism, and inhibition of tetracycline-inactivating enzymes. Frontiers Media S.A. 2018-05-30 /pmc/articles/PMC5988894/ /pubmed/29899733 http://dx.doi.org/10.3389/fmicb.2018.01058 Text en Copyright © 2018 Markley and Wencewicz. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Markley, Jana L.
Wencewicz, Timothy A.
Tetracycline-Inactivating Enzymes
title Tetracycline-Inactivating Enzymes
title_full Tetracycline-Inactivating Enzymes
title_fullStr Tetracycline-Inactivating Enzymes
title_full_unstemmed Tetracycline-Inactivating Enzymes
title_short Tetracycline-Inactivating Enzymes
title_sort tetracycline-inactivating enzymes
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988894/
https://www.ncbi.nlm.nih.gov/pubmed/29899733
http://dx.doi.org/10.3389/fmicb.2018.01058
work_keys_str_mv AT markleyjanal tetracyclineinactivatingenzymes
AT wencewicztimothya tetracyclineinactivatingenzymes

Ejemplares similares